Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $25.97 -1.67%
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets
- KB Home (KBH) PT Lowered to $50 at RBC Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
